Fibroblast growth factor 23 and the antiproteinuric response to dietary sodium restriction during renin-angiotensin-aldosterone system blockade

American Journal of Kidney Diseases

Volumn 65, Issue 2, 2015, Pages 259-266

  Humalda, Jelmer K ^a   Lambers Heerspink, Hiddo J ^b   Kwakernaak, Arjan J ^a   Slagman, Maartje C J ^a   Waanders, Femke ^a   Vervloet, Marc G ^c   Ter Wee, Pieter M ^c   Navis, Gerjan ^a   De Borst, Martin H ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

(ACE); (ARB); angiotensin converting enzyme; blockade sodium restriction antiproteinuric; chronic kidney disease (CKD); factor 23 (FGF 23); Fibroblast growth; inhibitor; phosphaturic hormone proteinuria renin angiotensin aldosterone system (RAAS); volume overload angiotensin receptor blocker

Indexed keywords

CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBROBLAST GROWTH FACTOR 23; PHOSPHATE; RENIN; SODIUM; VALSARTAN; ALDOSTERONE; BIOLOGICAL MARKER; FIBROBLAST GROWTH FACTOR; SALT INTAKE;

ADULT; ARTICLE; CALCIUM BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE CLEARANCE; CROSSOVER PROCEDURE; DIASTOLIC BLOOD PRESSURE; FEMALE; HUMAN; MALE; OBSERVATIONAL STUDY; PHOSPHATE BLOOD LEVEL; POST HOC ANALYSIS; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SODIUM BLOOD LEVEL; SODIUM EXCRETION; SODIUM INTAKE; SODIUM RESTRICTION; TREATMENT RESPONSE; AGED; BLOOD; DIET THERAPY; DRUG EFFECTS; MIDDLE AGED; PHYSIOLOGY; SALT INTAKE; TRENDS;

ADULT; AGED; ALDOSTERONE; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BIOLOGICAL MARKERS; CROSS-OVER STUDIES; DIET, SODIUM-RESTRICTED; FEMALE; FIBROBLAST GROWTH FACTORS; HUMANS; MALE; MIDDLE AGED; PROTEINURIA; RENIN-ANGIOTENSIN SYSTEM; SODIUM CHLORIDE, DIETARY;

EID: 84921614751     PISSN: 02726386     EISSN: 15236838     Source Type: Journal    
DOI: 10.1053/j.ajkd.2014.07.022     Document Type: Article

References (35)

1. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia) Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy Lancet 349 9069 1997 1857 1863
2. I. Giatras, J. Lau, and A.S. Levey Effect of angiotensin-converting enzyme inhibitors on the progression of nondiabetic renal disease: a meta-analysis of randomized trials. angiotensin-converting-enzyme inhibition and progressive renal disease study group Ann Intern Med 127 5 1997 337 345
3. R.E. Schmieder, J.F. Mann, and H. Schumacher Changes in albuminuria predict mortality and morbidity in patients with vascular disease J Am Soc Nephrol 22 7 2011 1353 1364
4. P. Ruggenenti, A. Perna, G. Remuzzi GISEN Group Investigators Retarding progression of chronic renal disease: the neglected issue of residual proteinuria Kidney Int 63 6 2003 2254 2261
5. G.D. Laverman, D. de Zeeuw, and G. Navis Between-patient differences in the renal response to renin-angiotensin system intervention: clue to optimising renoprotective therapy? J Renin Angiotensin Aldosterone Syst 3 4 2002 205 213
6. H.J. Lambers Heerspink, M.H. de Borst, S.J. Bakker, and G.J. Navis Improving the efficacy of RAAS blockade in patients with chronic kidney disease Nat Rev Nephrol 9 2 2013 112 121
7. L. Vogt, F. Waanders, F. Boomsma, D. de Zeeuw, and G. Navis Effects of dietary sodium and hydrochlorothiazide on the antiproteinuric efficacy of losartan J Am Soc Nephrol 19 5 2008 999 1007
8. S.C. Hung, K.L. Kuo, and C.H. Peng Volume overload correlates with cardiovascular risk factors in patients with chronic kidney disease Kidney Int 85 3 2014 703 709
9. C. Zoccali, P. Ruggenenti, and A. Perna Phosphate may promote CKD progression and attenuate renoprotective effect of ACE inhibition J Am Soc Nephrol 22 10 2011 1923 1930
10. T. Isakova, P. Wahl, and G.S. Vargas Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease Kidney Int 79 12 2011 1370 1378
11. O.M. Gutierrez, M. Mannstadt, and T. Isakova Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis N Engl J Med 359 6 2008 584 592
12. D. Fliser, B. Kollerits, and U. Neyer Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) Study J Am Soc Nephrol 18 9 2007 2600 2608
13. T. Isakova, H. Xie, and W. Yang Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease JAMA 305 23 2011 2432 2439
14. M. Wolf, M.Z. Molnar, and A.P. Amaral Elevated fibroblast growth factor 23 is a risk factor for kidney transplant loss and mortality J Am Soc Nephrol 22 5 2011 956 966
15. J.H. Ix, M.G. Shlipak, C.L. Wassel, and M.A. Whooley Fibroblast growth factor-23 and early decrements in kidney function: the Heart and Soul Study Nephrol Dial Transplant 25 3 2010 993 997
16. M.G. Vervloet, A.D. van Zuilen, and A.C. Heijboer Fibroblast growth factor 23 is associated with proteinuria and smoking in chronic kidney disease: an analysis of the MASTERPLAN cohort BMC Nephrol 13 1 2012 20
17. S. Lundberg, A.R. Qureshi, S. Olivecrona, I. Gunnarsson, S.H. Jacobson, and T.E. Larsson FGF23, albuminuria, and disease progression in patients with chronic IgA nephropathy Clin J Am Soc Nephrol 7 5 2012 727 734
18. L.C. Baia, J.K. Humalda, M.G. Vervloet, G. Navis, S.J.L. Bakker, and M.H. de Borst Fibroblast growth factor 23 and cardiovascular mortality after kidney transplantation Clin J Am Soc Nephrol 8 11 2013 1968 1978
19. J.J. Scialla, H. Xie, and M. Rahman Fibroblast growth factor-23 and cardiovascular events in CKD J Am Soc Nephrol 25 2 2014 349 360
20. J.H. Ix, R. Katz, and B.R. Kestenbaum Fibroblast growth factor-23 and death, heart failure, and cardiovascular events in community-living individuals: CHS (Cardiovascular Health Study) J Am Coll Cardiol 60 3 2012 200 207
21. M.C. Slagman, F. Waanders, and M.H. Hemmelder Moderate dietary sodium restriction added to angiotensin converting enzyme inhibition compared with dual blockade in lowering proteinuria and blood pressure: randomised controlled trial BMJ 343 2011 d4366
22. C.R. Doorenbos, M.M. de Cuba, and L. Vogt Antiproteinuric treatment reduces urinary loss of vitamin D-binding protein but does not affect vitamin D status in patients with chronic kidney disease J Steroid Biochem Mol Biol 128 1-2 2012 56 61
23. S. Trenkel, C. Seifarth, H. Schobel, E.G. Hahn, and J. Hensen Ratio of serum aldosterone to plasma renin concentration in essential hypertension and primary aldosteronism Exp Clin Endocrinol Diabetes 110 2 2002 80 85
24. H. Buter, M.H. Hemmelder, G. Navis, P.E. de Jong, and D. de Zeeuw The blunting of the antiproteinuric efficacy of ACE inhibition by high sodium intake can be restored by hydrochlorothiazide Nephrol Dial Transplant 13 7 1998 1682 1685
25. V.L. Esnault, A. Ekhlas, C. Delcroix, M.G. Moutel, and J.M. Nguyen Diuretic and enhanced sodium restriction results in improved antiproteinuric response to RAS blocking agents J Am Soc Nephrol 16 2 2005 474 481
26. E.I. Ekinci, G. Thomas, and D. Thomas Effects of salt supplementation on the albuminuric response to telmisartan with or without hydrochlorothiazide therapy in hypertensive patients with type 2 diabetes are modulated by habitual dietary salt intake Diabetes Care 32 8 2009 1398 1403
27. O. Andrukhova, S. Slavic, U. Zeitz, V. Shalhoub, B. Lanske, and R.G. Erben FGF23 regulates renal sodium handling and blood pressure [abstract] J Am Soc Nephrol 23 2012 46A
28. A.B. Kramer, G.D. Laverman, H. van Goor, and G. Navis Inter-individual differences in anti-proteinuric response to ACEi in established Adriamycin nephrotic rats are predicted by pretreatment renal damage J Pathol 201 1 2003 160 167
29. Lindberg K, Amin R, Moe OW, et al. The kidney is the principal organ mediating klotho effects [published online ahead of print May 22, 2014]. J Am Soc Nephrol. http://dx.doi.org/10.1681/ASN.2013111209.
30. T. Shimada, Y. Yamazaki, and M. Takahashi Vitamin D receptor-independent FGF23 actions in regulating phosphate and vitamin D metabolism Am J Physiol Renal Physiol 289 5 2005 F1088 F1095
31. M.H. de Borst, M.G. Vervloet, P.M. ter Wee, and G. Navis Cross talk between the renin-angiotensin-aldosterone system and vitamin D-FGF-23-klotho in chronic kidney disease J Am Soc Nephrol 22 9 2011 1603 1609
32. I. Hamming, M.E. Cooper, and B.L. Haagmans The emerging role of ACE2 in physiology and disease J Pathol 212 1 2007 1 11
33. A.T. Lely, I. Hamming, H. van Goor, and G.J. Navis Renal ACE2 expression in human kidney disease J Pathol 204 5 2004 587 593
34. B. Dai, V. David, and A. Martin A comparative transcriptome analysis identifying FGF23 regulated genes in the kidney of a mouse CKD model PLoS One 7 9 2012 e44161
35. National Kidney Foundation. K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease: guideline 9 pharmacological therapy: nondiabetic kidney disease. http://www.ajkd.org/article/S0272-6386%2804%2900272-0/fulltext#Guideline%209:%20pharmacological%20therapy:%20nondiabetic%20kidney%20disease. Updated 2004. Accessed August 3, 2012.